Previous 10 | Next 10 |
Viveve 2.0 system and its consumable treatment tips can now be sold in over 30 countries in addition to the United States ENGLEWOOD, CO / ACCESSWIRE / April 11, 2019 / Viveve Medical Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced th...
We Found No Fundamental Justification For CFMS 400% Rally We at White Diamond Research are medical device experts. Recently, we have been exposing medical device companies that have inferior devices. Over the last eight months, we have published on Seeking Alpha bearish reports on the follow...
Viveve Medical, Inc. (VIVE) Q4 2018 Earnings Conference Call March 14, 2019 05:00 PM ET Company Participants Scott Durbin - CEO Jeannie Swindle - Senior Director of Corporate Communications Conference Call Participants Josh Jennings - Cowen Matt Wizman - Raymond James Jon...
Viveve Medical (NASDAQ: VIVE ): Q4 GAAP EPS of -$0.38 misses by $0.03 . More news on: Viveve Medical, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
ENGLEWOOD, CO / ACCESSWIRE / March 14, 2019 / Viveve Medical Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today reported financial results for the three months and full year ended December 31, 2018. "2018 was a year of solid progress even as we worke...
The following slide deck was published by Viveve Medical, Inc. in conjunction with this Read more ...
Viveve Medical (NASDAQ: VIVE ) has completed enrollment in its VIVEVE II trial, a randomized, double-blinded study to evaluate the safety and efficacy of its cryogen-cooled monopolar radiofrequency (CMRF) technology for the improvement of sexual function in women following vaginal chi...
Resultscould support a marketing application for an expanded U.S. indication forimprovement of sexual function in women ENGLEWOOD, CO / ACCESSWIRE / March 11, 2019 / Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, announced today th...
ENGLEWOOD, CO / ACCESSWIRE / March 7, 2019 / Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that it will report its fourth quarter and year-end 2018 financial results after the close of the U.S. financial markets on Thurs...
T2 Biosystems (TTOO) T2 Magnetic Resonance ("MR") technology, powered through their T2Dx Instrument, is a diagnostic system that can do a variety of blood tests from inserted panels. They just had a big launch in mid-2018 for the T2Bacteria which got FDA approved in May 2018 that was suppose...
News, Short Squeeze, Breakout and More Instantly...
Novonix Limited (NVNXF) is expected to report for quarter end 2023-12-31 MedAvail Holdings Inc. (MDVL) is expected to report for Q3 2023 Nobility Homes, Inc. (NOBH) is expected to report for quarter end 2023-10-31 Walgreens Boots Alliance Inc. (WBA) is expected to report $0.66 for Q1 ...
Disco Corporation ADR (DSCSY) is expected to report for Q2 2024 Sonic Foundry Inc. (SOFO) is expected to report for quarter end 2023-09-30 Sono Group N.V. (SEVCQ) is expected to report for quarter end 2023-09-30 Minim Inc (MINM) is expected to report for Q3 2023 Enel Spa ADR (ENLA...
Enel Spa ADR (ENLAY) is expected to report for Q3 2023 LEG Immobilien SE Registered Shares (LEGIF) is expected to report for Q3 2023 G. Willi-Food International Ltd. (WILC) is expected to report for Q3 2023 Worthington Steel Inc. (WS) is expected to report $0.15 for Q2 2024 Sonic ...